SAN DIEGO, Oct. 5, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Aethlon Hemopurifier® and HER2osome™ cancer therapy will be the subject of a presentation at the Exosomes and Microvesicles 2011 conference on October 17th. The event is being held at the Wyndham Lake Buena Vista Resort located in Walt Disney World, Florida. Dr. Annette Marleau, Director of Tumor Immunology at Aethlon Medical will give the presentation. Both the Aethlon Hemopurifier® and HER2osome™ represent novel exosome-targeted strategies to improve cancer treatment outcomes. Exosomes released by cancers have recently emerged to become therapeutic targets in cancer care, as they are implicated in cancer survival, growth, and metastasis. Researchers have also identified that cancer-released exosomes assist tumors in evading the response of the immune system.
About HER2osome™HER2osome™ provides a therapeutic strategy to maximize the ability of the immune system and established drug therapies to combat HER2+ breast cancer, which is characterized by aggressive growth and poor prognosis resulting from the over-expression of HER2 protein. HER2osome™ is a novel medical device, whose goal is to inhibit HER2+ breast cancer progression by reducing the circulatory presence of HER2 protein and tumor-secreted exosomes that contribute to the development and progression of breast cancer. Research publications indicate that breast cancer exosomes suppress the immune response, stimulate angiogenesis, contribute to the spread of metastasis, and inhibit the therapeutic benefit of Herceptin® (trastuzumab), a leading monoclonal antibod